Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $23.8600 (5.48%) ($22.5100 - $24.5300) on Wed. Jul. 8, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.56% (three month average) | RSI | 75 | Latest Price | $23.8600(5.48%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 4.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 7.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.28% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-4%) XLC(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.28% (StdDev 6.56%) | Hourly BBV | 0 () | Intraday Trend | 4.9% | | | |
|
5 Day Moving Average | $21.47(11.13%) | 10 Day Moving Average | $20.21(18.06%) | 20 Day Moving Average | $19.28(23.76%) | To recent high | 0% | To recent low | 140% | Market Cap | $3.022b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |